CTX、ADM联合CF+5-Fu持续滴注方案与CAF方案治疗晚期乳腺癌的疗效比较

目的 比较CTX、ADM联合CF 5-Fu持续滴注方案与CAF方案治疗晚期乳腺癌的近期疗效与毒性反应.方法 将64例晚期乳腺癌患者采用信封抽签法随机分组,CTX、ADM联合CF 5-Fu持续滴注方案为观察组,CAF方案为对照组,平均化疗2.5个周期.结果 观察组有效率为71.88%(23/32),对照组为43.75%(14/32),两组有效率比较有显著性差异,P＜0.05;观察组KPS改善率为75.00%(24/32),对照组46.88%(15/32),两组比较有显著性差异,P＜0.05;观察组白细胞下降及血小板减少分别为71.88%(23/32)、62.50%(20/32),对照组分别为43.75%(14/32)、28.13%(9/32),两组比较均有显著性差异,P＜0.05;观察组恶心呕吐、口腔粘膜炎、腹泻发生率分别为75.00%(24/32)、50.00%(16/32)、46.88%(15/32),对照组分别为50.00%(16/32)、18.75%(6/32)、21.88%(7/32),两组比较均有显著性差异,P＜0.05.结论 CTX、ADM联合CF 5-Fu持续滴注治疗晚期乳腺癌有效率高,毒性反应较明显,但病人可以耐受.

Efficacy Comparison Between Regimen CTX, ADM and Continuously Intravenous 5-Fu/CF and Regimen CAF to Treat Advanced Breast Cancer

Objective To compare the efficacy and toxicity of regimen CTX, ADM and continuously intravenous 5-Fu/CF and regimen CAF to treat advanced breast cancer. Methods 64 patients with advanced breast cancer were divided into two groups: CTX, ADM and 5-Fu/CF c.i.v. as observation group and CAF as control group, with chemotherapy averaging 2.5 cycles. Results When comparing between observation group and control group, response rates were 71.88% (23/32) v.s. 43.75% (14/32) (p<0.05), KPS score improving rates 75.00% (24/32) v.s. 46.88% (15/32) (p<0.05), leukopenia rates 71.88% (23/32) v.s. 43.75% 04/32) (p